Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
- 1 December 2010
- journal article
- review article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 21 (2), 71-84
- https://doi.org/10.3851/imp1688
Abstract
Oseltamivir and zanamivir are currently licensed worldwide for influenza treatment and chemoprophylaxis. Both drugs require twice-daily administration for 5 days for treatment. A new influenza drug, laninamivir (code name R-125489), and its prodrug form, CS-8958 (laninamivir octanoate or laninamivir prodrug), which are long-acting neuraminidase inhibitors, are introduced in this review. Laninamivir potently inhibited the neuraminidase activities of various influenza A and B viruses, including subtypes N1–N9, pandemic (2009) H1N1 virus, highly pathogenic avian influenza (HPAI) H5N1 viruses and oseltamivir-resistant viruses. Because of the long retention of laninamivir in mouse lungs after an intranasal administration of CS-8958, therapeutic administration of a single dose of CS-8958 showed superior efficacy to repeated administrations of zanamivir or oseltamivir in animal infection models for influenza A and B viruses. These include pandemic (2009) H1N1 virus and HPAI H5N1 virus. Prophylactic single administration of CS-8958, as early as 7 days prior to infection, also showed superior efficacy. Finally, the potential of a single inhalation of CS-8958 for influenza patients was demonstrated by clinical studies, and CS-8958 has been approved and is commercially available as Inavir® (Daiichi Sankyo Co., Ltd, Tokyo) in Japan.Keywords
This publication has 34 references indexed in Scilit:
- Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009The New England Journal of Medicine, 2009
- Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and MiceScience, 2009
- Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in FerretsScience, 2009
- In vitro and in vivo characterization of new swine-origin H1N1 influenza virusesNature, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansThe New England Journal of Medicine, 2009
- Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United StatesJAMA, 2006
- Human influenza A H5N1 virus related to a highly pathogenic avian influenza virusThe Lancet, 1998
- Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virusThe Lancet, 1998
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998
- Antiviral Activity of 1-Adamantanamine (Amantadine)Science, 1964